Literature DB >> 390986

A molecular basis of activation of the alternative pathway of human complement.

K F Austen, D T Fearon.   

Abstract

The fluid phase interaction of native C3, B, D and P continuously generates C3b; C3b complexes with B to permit cleavage-activation by D, thereby generating C3b, Bb, the amplification C3 convertase. C3b, Bb formed in the fluid phase or on a non-activating surface for the alternative pathway undergoes decay-dissociation through release of Bi, and the residual C3b undergoes cleavage inactivation by the C3b inactivator (C3bINA). The capacity of P to stabilize C3b, Bb and therby augment C3 cleavage is counterbalanced by beta 1H, which inactivates the convertase by displacing Bi and facilitates the inactivation of residual C3b by C3bINA. Transition to amplified C3 cleavage is achieved because the surface characteristics of an activating particle protect C3b from inactivation by C3bINA in the presence of beta 1H, and the stabilized alternative pathway convertase, P, C3b, Bb, from extrinsic decay-dissociation by beta 1H. Natural activating surfaces such as zymosan (Zy) and rabbit erythrocytes are relatively deficient in sialic acid residues as compared to non-activating surfaces such as sheep erythrocytes (Es). Sialic acid residues on C3b-bearing particles augment binding of beta 1H to favor competition with B, inactivation of C3b and decay-dissociation of C3b, Bb. The absence of this carbohydrate on the membrane in the environment of C3b results in low affinity binding of beta 1H, a circumstance that permits uptake of B to form the amplification convertase and impairs extrinsic decay of the C3-cleaving enzyme. This natural humoral host resistance reaction based on the relative content of sialic acid on target particles has a cellular counterpart in the capacity of human monocytes to engage in antibody-independent phagocytosis of sialic acid-deficient cells. Thus, the non-immune host may respond to such cells by dual humoral and cellular recognition mechanisms and this response may represent a primordial basis for protection against microbial invasion.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 390986

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

1.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

Review 3.  Electron microscopy of the first component of human complement.

Authors:  V N Schumaker; C J Strang; R L Siegel; M L Phillips; P H Poon
Journal:  Surv Immunol Res       Date:  1982

Review 4.  Complement in the brain.

Authors:  Robert Veerhuis; Henrietta M Nielsen; Andrea J Tenner
Journal:  Mol Immunol       Date:  2011-05-04       Impact factor: 4.407

5.  Meningococcal group W-135 and Y capsular polysaccharides paradoxically enhance activation of the alternative pathway of complement.

Authors:  Sanjay Ram; Lisa A Lewis; Sarika Agarwal
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

6.  Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis.

Authors:  Lisa A Lewis; David M Vu; Shreekant Vasudhev; Jutamas Shaughnessy; Dan M Granoff; Sanjay Ram
Journal:  MBio       Date:  2013-10-15       Impact factor: 7.867

7.  Staphylococcal protein Ecb impairs complement receptor-1 mediated recognition of opsonized bacteria.

Authors:  Hanne Amdahl; Karita Haapasalo; Lydia Tan; Taru Meri; Pentti I Kuusela; Jos A van Strijp; Suzan Rooijakkers; T Sakari Jokiranta
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

8.  Exceptional matters.

Authors:  Keith Peters
Journal:  Lancet       Date:  2004 Dec 11-17       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.